The panels began investigating Aduhelm’s approval and pricing in June 2021, just weeks after it won the FDA’s backing despite questions about the drug’s clinical benefit to patients.
Monday, December 23, 2024
House Dems raise issues with ‘atypical’ FDA review process for Alzheimer’s drug
Leave a Reply
Wireopedia is an automated news feed. The Wireopedia AI pulls from sources with different views so you can see the various sides of different arguments and make a decision for yourself. Wireopedia will be firmly committed to the public interest and democratic values.
Privacy Policy Terms and Conditions
